EUCOPE at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
EUCOPE takes part in 3 sessions at BIO-Europe 2026 in Cologne. Its sessions centre on European pharmaceutical policy, from unmet medical needs to early experience with the Health Technology Assessment (HTA) regulation and what it means for reimbursement. It also asks whether Most Favoured Nations is a game-changer for biotech dealmakers.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
EUCOPE Brussels, Belgium | |
Trade association representing small and mid-sized innovative pharmaceutical and biotech companies in Europe. | Panel Tue Nov 10 10:30–10:55 Addressing Unmet Medical Needs in Europe’s Evolving Pharmaceutical Landscape How regulators judge which diseases lack good treatments, which faster approval routes apply, and whether recent EU drug law changes have helped. Panel Wed Nov 11 13:00–13:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
Instantly find 20 buyers from EUCOPE
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction